Home| Professor of Haemostasis and Thrombosis |
Contact details:
| Tel: | +44 20 7377 7455 |
| Fax: | +44 20 7377 7016 |
| Email: | k.j.pasi@qmul.ac.uk |
| Address: | Academic Haematology Unit,, |
Biography
John Pasi has been Professor of Haemostasis and Thrombosis at Barts and the London since August 2003. This followed posts as Professor of Haematology at the University of Leicester and Head of Service at the University Hospitals of Leicester NHS Trust (1999-2003) and Consultant Haematologist / Honorary Senior Lecturer at the Royal Free Hospital and School of Medicine (1993-1999). He graduated from the University of Birmingham in 1983 and began his training in haematology at the Birmingham Children's Hospital, where he undertook his PhD research.
His major clinical interests are in all aspects of inherited and acquired bleeding and clotting disorders but most particularly thrombosis (including its prevention), haemophilia and von Willebrand's disease.
He has been actively involved in the development of national policy and guideline formulation across a broad range of haemostatic and thrombotic disorders. Along with these activities he has a longstanding interest in clinical training and has been active in developing newer models of training initiatives to encourage people into haematology sub-specialties.
Research Activity
Research interests lie in gene therapy for haemophilia, molecular pathology of von Willebrands disease, the link between cancer and thrombosis and the mechanisms of inhibitor development in haemophilia A. A gene therapy trial for using adeno- associated virus for the transfer of factor IX for haemophilia B has recently been approved in conjunction with colleagues at University College London .
Key Publications
• Jenkins PV, Pasi KJ , Perkins SJ. Molecular modelling of ligand and mutation sites of the Type A domains of human von Willebrand factor and their relevance to von Willebrand's disease Blood 1998: 91: 2032-2044
• Fields PA, Kowalczyk DW, Arruda VA , Armstrong E, McClelland M, Hagstrom J, Pasi KJ , Ertl HG, Herzog R, High KA Role of vector in activation of T cell subsets in immune response against secreted transgene product factor IX Molecular Therapy 2000:1: 225-235
• Roth DA, Kessler CM, Pasi KJ , Rup B, Courter SG, Tubridy K for the Recombinant Factor IX Study Group Human Recombinant Factor IX: Safety and Efficacy Studies in Patients With Hemophilia B Blood 2001: 98: 3600-3606
• Bayele HK, Murdock PJ, Perry DJ, Pasi KJ Simple shifts in redox/thiol balance that perturb blood coagulation FEBS Letters 2002: 510: 67-70
• Behrman M, Pasi J , Saint-Remy J-M, Kotitischke R, Kloft M. VWF modulates FVIII immunogenicity: comparative study of different plasma-derived and recombinant FVIII concentrates in a hemophilia A mouse model. Thrombosis and Haemostasis 2002: 88: 221-229
• Bowen DJ, Collins PW, Lester W, Cumming AM , Keeney SM, Grundy P, Enayat SM, Bolton-Maggs PHB, Keeling DM, Khair K, Tait RC, Wilde JT, Pasi KJ , Hill FGH, on behalf of UK Haemophilia Centre Doctors' Organization. The prevalence of the cysteine1584 variant of von Willebrand factor is increased in type 1 von Willebrand disease: co-segregation with increased susceptibility to AD AM TS13 proteolysis but not clinical phenotype. British Journal of Haematology, 2005: 128: 830-836
• Eikenboom J, Van Marion V, Putter H, Goodeve A, Rodeghiero F, Castaman G, Federici AB, Batlle J, Meyer D, Mazurier C, Goudemand J, Schneppenheim R, Budde U, Ingerslev J, Vorlova Z, Habart D, Holmberg L, Lethagen S, Pasi J , Hill F, Peake I. Linkage analysis in families diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 VWD. Journal of Thrombosis and Haemostasis 2006: 4: 774-782
• Cumming A, Grundy P, Keeney S, Lester W, Enayat S, Guilliatt A, Bowen D, Pasi J , Keeling D, Hill F, Bolton-Maggs PH, Hay C, Collins P, the UK Haemophilia Centre Doctors' Organisation. An investigation of the von Willebrand factor genotype in UK patients diagnosed to have type 1 von Willebrand disease. Thrombosis & Haemostasis. 2006: 96:630-41
• Tosetto A, Rodeghiero F, Castaman G, Bernardi M, Bertoncello K, Goodeve A, Federici AB, Batlle J, Meyer D, Mazurier C, Goudemand J, Eikenboom J, Schneppenheim R, Budde U, Ingerslev J, Vorlova Z, Habart D, Holmberg L, Lethagen S, Pasi J , Hill F, Peake I. Impact of plasma von Willebrand factor levels in the diagnosis of type 1 von Willebrand disease. Journal of Thrombosis and Haemostasis 2007: 5: 715-21
• Goodeve A, Eikenboom J, Castaman G, Rodeghiero F, Federici AB, Batlle J, Meyer D, Mazurier C, Goudemand J, Schneppenheim R, Budde U, Ingerslev J, Habart D, Vorlova Z, Holmberg L, Lethagen S, Pasi J , Hill F, Hashemi M, Baronciani L, Lambert F, Hallden C, Guilliatt A, Peake I. Phenotype and Genotype of a Cohort of Families Diagnosed with Type 1 von Willebrand Disease in the European Study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD). Blood 2007: 109: 112-121
